Pre-ANDA litigation: strategies and tactics for developing a drug product and patent portfolio
"This book, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that the pharmaceutical litigants could follow"--
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Chicago, Illinois
American Bar Association, Intellectual Property Law Section
[2022]
|
| Ausgabe: | Third edition |
| Schlagworte: | |
| Zusammenfassung: | "This book, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that the pharmaceutical litigants could follow"-- |
| Beschreibung: | xxix, 1110 Seiten Illustrationen 26 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048617923 | ||
| 003 | DE-604 | ||
| 005 | 20230310 | ||
| 007 | t | ||
| 008 | 221219s2022 a||| |||| 00||| eng d | ||
| 020 | |z 9781639051144 |c Hardcover |9 978-1-63905-114-4 | ||
| 020 | |z 1639051147 |9 1639051147 | ||
| 035 | |a (DE-599)BVBBV048617923 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-M382 | ||
| 245 | 1 | 0 | |a Pre-ANDA litigation |b strategies and tactics for developing a drug product and patent portfolio |c Kenneth L. Dorsney, editor-in-chief |
| 250 | |a Third edition | ||
| 264 | 1 | |a Chicago, Illinois |b American Bar Association, Intellectual Property Law Section |c [2022] | |
| 300 | |a xxix, 1110 Seiten |b Illustrationen |c 26 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 505 | 8 | |a Coordinating new drug application (NDA) and patent portfolio strategy -- Preclinical R&D -- Preclinical patent considerations -- Clinical trials and regulatory considerations -- Clinical trial-patent considerations -- Trademark and nonproprietary name considerations -- Investigational new drug (IND) and new drug applications (NDA) -- Regulatory exclusivity -- Overview of the NDA review process -- Orange Book listable patents -- Postmarketing regulatory requirements and life cycle management -- Continued patent portfolio development before the Patent Office -- Acquiring and in-licensing pharmaceutical products : due diligence issues -- Pre-litigation investigations and due diligence -- Market entry business considerations for generic companies -- Selection of generic drug candidates -- Intellectual property considerations related to generic products -- Preparation of noninfringement/invalidity legal opinions -- Preparing your ANDA with an eye toward approval and litigation -- Section VIII carve-outs -- Obtaining ANDA approval and right to market -- Providing notice to the NDA holder -- Pharmaceutical supply chain : patent considerations -- Evaluating scenarios for launch, including marketing and manufacturing developments -- Interplay between inter partes review (IPR) and ANDA litigation -- Citizen petitions -- Expedited regulatory pathways -- REMS 101 for ANDA litigators and counselors -- Regulatory compliance : inspections and their consequences -- Biologic drugs and the Biologics Price Competition and Innovation Act -- Drug approval considerations and patent linkage system in China -- Pharmaceutical regulation and approval in foreign countries | |
| 520 | |a "This book, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that the pharmaceutical litigants could follow"-- | ||
| 650 | 4 | |a Abbreviated New Drug Application | |
| 650 | 4 | |a Drugs / United States / Patents | |
| 650 | 4 | |a Drugs / Law and legislation / United States | |
| 650 | 4 | |a Patent laws and legislation / United States | |
| 650 | 4 | |a Drug approval / United States | |
| 650 | 4 | |a Drug development / United States | |
| 650 | 4 | |a Pharmacy / Law and legislation / United States | |
| 650 | 4 | |a Pharmaceutical industry / United States | |
| 650 | 4 | |a Biotechnology / United States / Patents | |
| 650 | 7 | |a Biotechnology |2 fast | |
| 650 | 7 | |a Drug approval |2 fast | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Drugs / Law and legislation |2 fast | |
| 650 | 7 | |a Drugs / Patents |2 fast | |
| 650 | 7 | |a Patent laws and legislation |2 fast | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Pharmacy / Law and legislation |2 fast | |
| 651 | 7 | |a United States |2 fast | |
| 700 | 1 | |a Dorsney, Kenneth L. |0 (DE-588)1218108266 |4 edt | |
| 710 | 2 | |a American Bar Association |b Section of Intellectual Property Law |e Sonstige |0 (DE-588)5197369-8 |4 oth | |
| 775 | 0 | 8 | |i Revision of |t Pre-ANDA litigation |b Second edition |d Chicago, Illinois : American Bar Association, Section of Intellectual Property Law, [2018] |
| 776 | 0 | 8 | |i Online version |t Pre-ANDA litigation |b Third edition |d Chicago, Illinois : American Bar Association, [2022] |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033993185 | ||
Datensatz im Suchindex
| _version_ | 1804184677172379648 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Dorsney, Kenneth L. |
| author2_role | edt |
| author2_variant | k l d kl kld |
| author_GND | (DE-588)1218108266 |
| author_facet | Dorsney, Kenneth L. |
| building | Verbundindex |
| bvnumber | BV048617923 |
| contents | Coordinating new drug application (NDA) and patent portfolio strategy -- Preclinical R&D -- Preclinical patent considerations -- Clinical trials and regulatory considerations -- Clinical trial-patent considerations -- Trademark and nonproprietary name considerations -- Investigational new drug (IND) and new drug applications (NDA) -- Regulatory exclusivity -- Overview of the NDA review process -- Orange Book listable patents -- Postmarketing regulatory requirements and life cycle management -- Continued patent portfolio development before the Patent Office -- Acquiring and in-licensing pharmaceutical products : due diligence issues -- Pre-litigation investigations and due diligence -- Market entry business considerations for generic companies -- Selection of generic drug candidates -- Intellectual property considerations related to generic products -- Preparation of noninfringement/invalidity legal opinions -- Preparing your ANDA with an eye toward approval and litigation -- Section VIII carve-outs -- Obtaining ANDA approval and right to market -- Providing notice to the NDA holder -- Pharmaceutical supply chain : patent considerations -- Evaluating scenarios for launch, including marketing and manufacturing developments -- Interplay between inter partes review (IPR) and ANDA litigation -- Citizen petitions -- Expedited regulatory pathways -- REMS 101 for ANDA litigators and counselors -- Regulatory compliance : inspections and their consequences -- Biologic drugs and the Biologics Price Competition and Innovation Act -- Drug approval considerations and patent linkage system in China -- Pharmaceutical regulation and approval in foreign countries |
| ctrlnum | (DE-599)BVBBV048617923 |
| edition | Third edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04156nam a2200541 c 4500</leader><controlfield tag="001">BV048617923</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20230310 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">221219s2022 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781639051144</subfield><subfield code="c">Hardcover</subfield><subfield code="9">978-1-63905-114-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1639051147</subfield><subfield code="9">1639051147</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048617923</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pre-ANDA litigation</subfield><subfield code="b">strategies and tactics for developing a drug product and patent portfolio</subfield><subfield code="c">Kenneth L. Dorsney, editor-in-chief</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Third edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Chicago, Illinois</subfield><subfield code="b">American Bar Association, Intellectual Property Law Section</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxix, 1110 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">26 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Coordinating new drug application (NDA) and patent portfolio strategy -- Preclinical R&D -- Preclinical patent considerations -- Clinical trials and regulatory considerations -- Clinical trial-patent considerations -- Trademark and nonproprietary name considerations -- Investigational new drug (IND) and new drug applications (NDA) -- Regulatory exclusivity -- Overview of the NDA review process -- Orange Book listable patents -- Postmarketing regulatory requirements and life cycle management -- Continued patent portfolio development before the Patent Office -- Acquiring and in-licensing pharmaceutical products : due diligence issues -- Pre-litigation investigations and due diligence -- Market entry business considerations for generic companies -- Selection of generic drug candidates -- Intellectual property considerations related to generic products -- Preparation of noninfringement/invalidity legal opinions -- Preparing your ANDA with an eye toward approval and litigation -- Section VIII carve-outs -- Obtaining ANDA approval and right to market -- Providing notice to the NDA holder -- Pharmaceutical supply chain : patent considerations -- Evaluating scenarios for launch, including marketing and manufacturing developments -- Interplay between inter partes review (IPR) and ANDA litigation -- Citizen petitions -- Expedited regulatory pathways -- REMS 101 for ANDA litigators and counselors -- Regulatory compliance : inspections and their consequences -- Biologic drugs and the Biologics Price Competition and Innovation Act -- Drug approval considerations and patent linkage system in China -- Pharmaceutical regulation and approval in foreign countries</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"This book, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that the pharmaceutical litigants could follow"--</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abbreviated New Drug Application</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / United States / Patents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Law and legislation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patent laws and legislation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug approval / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy / Law and legislation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology / United States / Patents</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biotechnology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug approval</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Law and legislation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Patents</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patent laws and legislation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacy / Law and legislation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorsney, Kenneth L.</subfield><subfield code="0">(DE-588)1218108266</subfield><subfield code="4">edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">American Bar Association</subfield><subfield code="b">Section of Intellectual Property Law</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)5197369-8</subfield><subfield code="4">oth</subfield></datafield><datafield tag="775" ind1="0" ind2="8"><subfield code="i">Revision of</subfield><subfield code="t">Pre-ANDA litigation</subfield><subfield code="b">Second edition</subfield><subfield code="d">Chicago, Illinois : American Bar Association, Section of Intellectual Property Law, [2018]</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Online version</subfield><subfield code="t">Pre-ANDA litigation</subfield><subfield code="b">Third edition</subfield><subfield code="d">Chicago, Illinois : American Bar Association, [2022]</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033993185</subfield></datafield></record></collection> |
| geographic | United States fast |
| geographic_facet | United States |
| id | DE-604.BV048617923 |
| illustrated | Illustrated |
| index_date | 2024-07-03T21:13:16Z |
| indexdate | 2024-07-10T09:43:08Z |
| institution | BVB |
| institution_GND | (DE-588)5197369-8 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033993185 |
| open_access_boolean | |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | xxix, 1110 Seiten Illustrationen 26 cm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | American Bar Association, Intellectual Property Law Section |
| record_format | marc |
| spelling | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio Kenneth L. Dorsney, editor-in-chief Third edition Chicago, Illinois American Bar Association, Intellectual Property Law Section [2022] xxix, 1110 Seiten Illustrationen 26 cm txt rdacontent n rdamedia nc rdacarrier Coordinating new drug application (NDA) and patent portfolio strategy -- Preclinical R&D -- Preclinical patent considerations -- Clinical trials and regulatory considerations -- Clinical trial-patent considerations -- Trademark and nonproprietary name considerations -- Investigational new drug (IND) and new drug applications (NDA) -- Regulatory exclusivity -- Overview of the NDA review process -- Orange Book listable patents -- Postmarketing regulatory requirements and life cycle management -- Continued patent portfolio development before the Patent Office -- Acquiring and in-licensing pharmaceutical products : due diligence issues -- Pre-litigation investigations and due diligence -- Market entry business considerations for generic companies -- Selection of generic drug candidates -- Intellectual property considerations related to generic products -- Preparation of noninfringement/invalidity legal opinions -- Preparing your ANDA with an eye toward approval and litigation -- Section VIII carve-outs -- Obtaining ANDA approval and right to market -- Providing notice to the NDA holder -- Pharmaceutical supply chain : patent considerations -- Evaluating scenarios for launch, including marketing and manufacturing developments -- Interplay between inter partes review (IPR) and ANDA litigation -- Citizen petitions -- Expedited regulatory pathways -- REMS 101 for ANDA litigators and counselors -- Regulatory compliance : inspections and their consequences -- Biologic drugs and the Biologics Price Competition and Innovation Act -- Drug approval considerations and patent linkage system in China -- Pharmaceutical regulation and approval in foreign countries "This book, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, is an in-depth resource for learning about and planning for ANDA litigations and all the different avenues that the pharmaceutical litigants could follow"-- Abbreviated New Drug Application Drugs / United States / Patents Drugs / Law and legislation / United States Patent laws and legislation / United States Drug approval / United States Drug development / United States Pharmacy / Law and legislation / United States Pharmaceutical industry / United States Biotechnology / United States / Patents Biotechnology fast Drug approval fast Drug development fast Drugs / Law and legislation fast Drugs / Patents fast Patent laws and legislation fast Pharmaceutical industry fast Pharmacy / Law and legislation fast United States fast Dorsney, Kenneth L. (DE-588)1218108266 edt American Bar Association Section of Intellectual Property Law Sonstige (DE-588)5197369-8 oth Revision of Pre-ANDA litigation Second edition Chicago, Illinois : American Bar Association, Section of Intellectual Property Law, [2018] Online version Pre-ANDA litigation Third edition Chicago, Illinois : American Bar Association, [2022] |
| spellingShingle | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio Coordinating new drug application (NDA) and patent portfolio strategy -- Preclinical R&D -- Preclinical patent considerations -- Clinical trials and regulatory considerations -- Clinical trial-patent considerations -- Trademark and nonproprietary name considerations -- Investigational new drug (IND) and new drug applications (NDA) -- Regulatory exclusivity -- Overview of the NDA review process -- Orange Book listable patents -- Postmarketing regulatory requirements and life cycle management -- Continued patent portfolio development before the Patent Office -- Acquiring and in-licensing pharmaceutical products : due diligence issues -- Pre-litigation investigations and due diligence -- Market entry business considerations for generic companies -- Selection of generic drug candidates -- Intellectual property considerations related to generic products -- Preparation of noninfringement/invalidity legal opinions -- Preparing your ANDA with an eye toward approval and litigation -- Section VIII carve-outs -- Obtaining ANDA approval and right to market -- Providing notice to the NDA holder -- Pharmaceutical supply chain : patent considerations -- Evaluating scenarios for launch, including marketing and manufacturing developments -- Interplay between inter partes review (IPR) and ANDA litigation -- Citizen petitions -- Expedited regulatory pathways -- REMS 101 for ANDA litigators and counselors -- Regulatory compliance : inspections and their consequences -- Biologic drugs and the Biologics Price Competition and Innovation Act -- Drug approval considerations and patent linkage system in China -- Pharmaceutical regulation and approval in foreign countries Abbreviated New Drug Application Drugs / United States / Patents Drugs / Law and legislation / United States Patent laws and legislation / United States Drug approval / United States Drug development / United States Pharmacy / Law and legislation / United States Pharmaceutical industry / United States Biotechnology / United States / Patents Biotechnology fast Drug approval fast Drug development fast Drugs / Law and legislation fast Drugs / Patents fast Patent laws and legislation fast Pharmaceutical industry fast Pharmacy / Law and legislation fast |
| title | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio |
| title_auth | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio |
| title_exact_search | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio |
| title_exact_search_txtP | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio |
| title_full | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio Kenneth L. Dorsney, editor-in-chief |
| title_fullStr | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio Kenneth L. Dorsney, editor-in-chief |
| title_full_unstemmed | Pre-ANDA litigation strategies and tactics for developing a drug product and patent portfolio Kenneth L. Dorsney, editor-in-chief |
| title_short | Pre-ANDA litigation |
| title_sort | pre anda litigation strategies and tactics for developing a drug product and patent portfolio |
| title_sub | strategies and tactics for developing a drug product and patent portfolio |
| topic | Abbreviated New Drug Application Drugs / United States / Patents Drugs / Law and legislation / United States Patent laws and legislation / United States Drug approval / United States Drug development / United States Pharmacy / Law and legislation / United States Pharmaceutical industry / United States Biotechnology / United States / Patents Biotechnology fast Drug approval fast Drug development fast Drugs / Law and legislation fast Drugs / Patents fast Patent laws and legislation fast Pharmaceutical industry fast Pharmacy / Law and legislation fast |
| topic_facet | Abbreviated New Drug Application Drugs / United States / Patents Drugs / Law and legislation / United States Patent laws and legislation / United States Drug approval / United States Drug development / United States Pharmacy / Law and legislation / United States Pharmaceutical industry / United States Biotechnology / United States / Patents Biotechnology Drug approval Drug development Drugs / Law and legislation Drugs / Patents Patent laws and legislation Pharmaceutical industry Pharmacy / Law and legislation United States |
| work_keys_str_mv | AT dorsneykennethl preandalitigationstrategiesandtacticsfordevelopingadrugproductandpatentportfolio AT americanbarassociationsectionofintellectualpropertylaw preandalitigationstrategiesandtacticsfordevelopingadrugproductandpatentportfolio |